China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with an undisclosed firm from Indonesia. The collaboration will focus on the localized production of molecular diagnostic reagents and equipment, as well as other in vitro diagnostic (IVD) products. The partnership aims to train local molecular diagnostic professionals, enhance disease prevention and control standards, upgrade primary healthcare facilities, and support the establishment of a disease monitoring network in Indonesia.
Local Presence and Customer Service Network
Sansure Biotech has already established a presence in Indonesia, having set up a national customer service network with local partners. This local footprint is expected to facilitate the implementation of the partnership’s goals and contribute to the improvement of molecular diagnostics capabilities within the country.
Aim of the Partnership
The partnership’s objectives align with broader public health goals, including the enhancement of disease prevention and control. By upgrading primary healthcare facilities and establishing a robust disease monitoring network, the collaboration aims to improve overall healthcare standards and outcomes in Indonesia.-Fineline Info & Tech
